FLT3-mutated AML: standards of care and ongoing investigation Authors: Ly V. Do, Jessica J. Jorgensen, Kieran D. Sahasrabudhe Published: 2026 ABSTRACT Acute myeloid leukemia (AML) is characterized by the rapid, unchecked clonal proliferation of myeloid precursor cells. It is the most common type of acute leukemia in adults and exhibits significant molecular heterogeneity. FLT3 mutations are among the most common and well-described genetic mutations in AML; they worsen overall survival and increase the relapse rate. Treatment options for FLT3-mutated AML are rapidly expanding, with an increasing number of FLT3 inhibitors being incorporated into treatment regimens. This review provides an overview of the role of FLT3 inhibitors in the current standard of care therapy in both the newly diagnosed and relapsed/refractory settings. Additionally, it highlights the areas of key ongoing investigations in the treatment of FLT3-mutated AML. Introduction Acute Myeloid Leukemia (AML) is an aggressive myeloid neoplasm that results from the uncontrolled clonal expansion of myeloid stem cells in the bone marrow. Mutations affecting the FMS-like tyrosine kinase 3 (FLT3) protein are observed in approximately 30% of newly diagnosed AML cases [1]. The FLT3 protein is a class III receptor tyrosine kinase (RTK) that is extensively involved in multiple pathways that regulate hematopoiesis. Like other RTKs, the receptor is activated by the binding of the FLT3 ligand to the extracellular domain, leading to autophosphorylation, dimerization, and activation of the receptor with a subsequent downstream signaling cascade, resulting in the activation of multiple cytoplasmic effector molecules involved in regulating apoptosis, cellular proliferation, and differentiation of hematopoietic cells in the bone marrow [2]. FLT3 is overexpressed in myeloid blasts in most AML cases [3]. There are two well-described types of activating FLT3 mutations in AML that lead to the constitutive activation of the protein, resulting in ligand-independent downstream signaling and increased cellular proliferation. These mutations are characterized by internal tandem duplications involving the juxtamembrane domain of the protein (FLT3-ITD mutations) or point mutations (missense mutations, deletions, and insertions) in the tyrosine kinase domain (FLT3-TKD mutations). Of the two types of FLT3 mutations, FLT3-ITD mutations are more common, found in 20%−25% of AML cases, whereas FLT3-TKD mutations are only found in 5%–6% [4]. FLT3-ITD mutations have been shown to adversely affect prognosis in multiple studies [5, 6]. However, the prognostic relevance of FLT3-TKD mutations is unclear, and these mutations have not been found to exert a consistent prognostic impact [7]. AML cases with FLT3-ITD mutations are classified in the intermediate-risk category in both the European LeukemiaNet (ELN) 2022 prognostic classification system for patients receiving intensive frontline chemotherapy and the ELN 2024 prognostic classification system for patients receiving less intensive venetoclax-based frontline therapy [8, 9]. The guidelines on AML management described in the 2025 consensus by the National Comprehensive Cancer Network® in the United States (NCCN®) and the 2022 consensus by the ELN recommend that FLT3 mutation status be assessed at the time of initial AML diagnosis and in the context of relapsed disease [10]. Despite the rise in next-generation sequencing (NGS) for the efficient and accurate detection of genetic mutations in AML, polymerase chain reaction (PCR) with fragment analysis remains the gold standard for the detection of FLT3 mutations. This is because NGS can miss large FLT3-ITD mutations, especially at low variant allele frequencies (< 5%), an issue that is not observed with PCR with fragment analysis [11, 12]. NCCN and ELN guidelines recommend allogeneic hematopoietic stem cell transplantation (alloHSCT) in the first remission for patients with FLT3-ITD-mutated AML. Transplants are also recommended for patients with FLT3-TKD mutated AML when the disease is classified as an intermediate or adverse risk based on the presence of concurrent cytogenetic and molecular findings. In addition to its prognostic implications, the presence of FLT3 mutations has direct therapeutic implications, with the advent of FLT3 inhibitors, a diverse group of small-molecule inhibitors of the FLT3 protein that play important roles in the treatment of FLT3-mutated AML. Type 1 FLT3 inhibitors (including midostaurin, gilteritinib, and crenolanib) are active against both FLT3-ITD and FLT3-TKD mutations, whereas type 2 FLT3 inhibitors (including sorafenib and quizartinib) are active against only FLT3-ITD mutations [13]. Based on their receptor specificity, FLT3 inhibitors can be classified as first- and second-generation inhibitors. First-generation inhibitors, including midostaurin and sorafenib, are less specific for FLT3, and thus have more off-target effects. Second-generation FLT3 inhibitors, including quizartinib, crenolanib, and gilteritinib, are more specific and potent against FLT3 and thus have fewer off-target effects. Over the past decade, the incorporation of FLT3 inhibitors has expanded the treatment of patients with FLT3-mutated AML. The mechanism of action of FLT3 Inhibitors is illustrated in Fig. 1.Fig. 1Mechanism of action of FLT3 inhibitorsFLT3 mutations lead to constitutive activation of the FLT3 tyrosine kinase protein. This results in increased dowstream signaling, thereby promoting unregulated cell growth, proliferation, and survival. This dowstream signaling is blocked by FLT3 inhibitors. Abbreviations: FLT3: FMS like tyrosine kinase 3; ITD: Internal tandem duplication, TKD: Tyrosine kinase domain: STAT5: Signal Transducer and Activator of Transcription 5: MAPK: Mitogen-activated protien kinases; PI3K: Phosphoinositide-3 kinases; AKT: AKT Serine/Threonine protein kinases. Created with BioRender.com Mechanism of action of FLT3 inhibitors FLT3 mutations lead to constitutive activation of the FLT3 tyrosine kinase protein. This results in increased dowstream signaling, thereby promoting unregulated cell growth, proliferation, and survival. This dowstream signaling is blocked by FLT3 inhibitors. Abbreviations: FLT3: FMS like tyrosine kinase 3; ITD: Internal tandem duplication, TKD: Tyrosine kinase domain: STAT5: Signal Transducer and Activator of Transcription 5: MAPK: Mitogen-activated protien kinases; PI3K: Phosphoinositide-3 kinases; AKT: AKT Serine/Threonine protein kinases. Created with BioRender.com FLT3 inhibitors as standard of care Frontline therapy for patients who are eligible for intensive chemotherapy Midostaurin One of the first landmark studies involving a FLT3 inhibitor was the phase III RATIFY trial, which assessed the outcomes in patients aged 18–59 with newly diagnosed FLT3-ITD- or TKD-mutated AML treated with intensive chemotherapy combined with midostaurin, a first-generation, type 1 FLT3 inhibitor. Intensive induction chemotherapy consisted of cytarabine and daunorubicin given in a traditional “7 + 3” fashion. The patients were randomized to receive either standard induction chemotherapy combined with midostaurin or standard induction chemotherapy combined with placebo. Following induction therapy, patients in remission completed up to four cycles of consolidation therapy combining high-dose cytarabine with either midostaurin or placebo. Patients who achieved remission were allowed to undergo alloHSCT at the discretion of the investigator. Patients in remission after completing induction and consolidation therapies who did not undergo alloHSCT received maintenance therapy with single-agent midostaurin or placebo for up to 12 months. In total, 717 patients were enrolled in this study. The initial findings were notable for superior event-free survival (EFS) and overall survival (OS) in patients receiving midostaurin. Median OS was 74.7 months in the experimental arm versus 25.6 months in the control arm at a median follow-up of 59 months with a 22% lower risk of death in patients receiving midostaurin (HR 0.78; 95% CI: 0.63–0.96; p = 0.009) [14]. The results of this study led to the approval of midostaurin combined with induction and consolidation chemotherapy in patients newly diagnosed with FLT3-ITD and TKD-mutated AML by the United States Food and Drug Administration (FDA). In 2024, the results of a 10-year follow-up study demonstrated that the benefits of midostaurin were maintained over time. Notably, the OS effect was still greater in the experimental arm at 10 years but was slightly diminished compared to earlier time points, which was attributed to patient aging. The 10-year OS was estimated to be 43.7% in the midostaurin arm and 38.6% in the placebo arm (p = 0.0485). This study demonstrated that alloHSCT in the first remission was associated with a significant survival benefit, with a 10-year OS of 56% in patients who underwent alloHSCT versus 35.8% in patients who did not undergo alloHSCT (p = 0.001). Among the more than 400 patients transplanted in first remission, randomization to midostaurin was associated with a marginal 10-year survival benefit compared to randomization to placebo (61.5% vs. 49%, p = 0.064). When censoring for transplantation in first complete remission (CR1), there was a trend towards superior OS in patients randomized to the midostaurin group, which was not statistically significant. The effect of midostaurin maintenance therapy on patients who did not undergo transplantation was also assessed. In ELN-favorable and intermediate-risk patients, midostaurin maintenance reduced the risk of relapse compared to placebo maintenance; however, it did not reduce the risk in ELN-adverse-risk patients. In addition, midostaurin maintenance therapy did not show any overall survival benefit [15]. Due to these results and the relatively small number of patients who received midostaurin maintenance in the RATIFY trial, midostaurin was not approved for maintenance therapy by the FDA. Quizartinib Quizartinib is a second-generation type 1I FLT3 inhibitor with activity against FLT3-ITD mutated AML. Quizartinib was evaluated in the QuANTUM-First trial, a randomized, double-blind, placebo-controlled phase III study across 193 institutions in 26 countries. This trial enrolled patients aged 18–75 years who were newly diagnosed with FLT3-ITD mutated AML. The patients received standard induction chemotherapy (cytarabine + anthracycline) plus quizartinib or a placebo. Patients who achieved remission with induction therapy then received up to four cycles of consolidation therapy with high dose cytarabine combined with either quizartinib or placebo. Patients could also undergo alloHSCT at the discretion of the investigator. Following consolidation therapy or transplantation, the patients received maintenance therapy with single-agent quizartinib or placebo for up to 3 years. Among 539 enrollees, those treated with quizartinib experienced a significant survival advantage, with median OS of 31.9 months for patients who received quizartinib versus 15.1 months in the placebo group at a median follow-up of 39.2 months (HR 0.78; p = 0.032). This study led to the FDA approval for the combination of quizartinib with intensive induction and consolidation chemotherapy in patients with newly diagnosed FLT3-ITD mutated AML [16]. There are several key differences between the RATIFY trial for midostaurin and the QuANTUM-First trial for quizartinib. The QuANTUM-First trial included only patients with FLT3-ITD mutations, whereas the RATIFY trial included patients with FLT3-ITD and TKD mutations, based on the respective mechanisms of action of quizartinib and midostaurin. QuANTUM-First included patients between the ages of 18–75, whereas the RATIFY trial included only patients aged up to 59 years. Therefore, quizartinib has an on-label indication for patients over the age of 60 years, whereas midostaurin does not. Quizartinib showed a decreased risk of relapse in patients aged < 60 years and > 60 years when the QuANTUM-First results were stratified by age. However, the relapse-free survival (RFS) and EFS associated with quizartinib were less pronounced in patients aged > 60 years than in younger patients [17]. Another key difference between RATIFY and QuANTUM-First pertains to the maintenance therapy. In the RATIFY trial, patients completing induction and consolidation therapy who did not undergo alloHSCT received maintenance midostaurin or placebo. Midostaurin maintenance did not demonstrate a survival benefit compared to the placebo. In the QuANTUM-First trial, patients received maintenance quizartinib or placebo for up to 3 years following the completion of consolidation chemotherapy or post-transplant maintenance. A subsequent analysis assessing the benefit of quizartinib maintenance therapy found that maintenance quizartinib was associated with a survival benefit in patients who did not undergo alloHSCT but was not associated with a survival benefit in patients who had undergone alloHSCT [18]. Thus, quizartinib is currently approved by the FDA as a maintenance therapy for up to 3 years in patients who do not undergo alloHSCT. Additional cross-trial differences existed between the RATIFY and QuANTUM-First trials. The RATIFY trial included patients with a FLT3 mutant-to-wild type allelic ratio of ≥ 0.05 while the QuANTUM-First trial included patients with a FLT3 mutant-to-wild type allelic ratio of ≥ 0.03. The anthracycline backbone in the RATIFY trial was daunorubicin, whereas the QuANTUM-First trial allowed daunorubicin or idarubicin. The QuANTUM-First trial was conducted after the RATIFY trial, which is an important consideration in the evolution of supportive care practices. Based on these significant differences, a cross-trial efficacy comparison is not valid or appropriate. Currently, there are no head-to-head trials directly comparing quizartinib to midostaurin when combined with intensive chemotherapy, leading to an equipoise regarding which therapy is superior for FLT3-ITD mutated AML. Some limited preclinical and retrospective data suggest the potentially increased potency and efficacy of quizartinib compared to midostaurin in this setting [19, 20]. However, these analyses are currently hypothesis generating and should not be used to inform clinical practice. Frontline therapy for patients who are ineligible for intensive chemotherapy Many patients with newly diagnosed AML are deemed ineligible for intensive chemotherapy based on their age, performance status, or comorbidities. Historically, the treatment options for this patient population have been very limited [21]. Over the past decade, significant therapeutic developments have been made for this subset of patients. Currently, the standard frontline treatment in the majority of these patients is a combination of the Bcl-2 inhibitor venetoclax and the hypomethylating agent azacitidine, based on the phase III Viale-A trial, in which venetoclax + azacitidine yielded superior OS compared to azacitidine monotherapy [22]. This combination was approved by the FDA as a frontline therapy for this patient population in 2020. In a subgroup analysis of patients with FLT3-mutated AML treated in the Viale-A study, the combination of venetoclax with azacitidine resulted in an improved composite complete remission (CRc) rate compared to the control regimen (72.4% vs. 36.4%; p = 0.02). A follow-up study assessed pooled outcomes in patients with FLT3-mutated AML treated with Viale-A and an earlier phase Ib study of venetoclax combined with either azacitidine or decitabine [23]. This study found that the CRc rate among patients with FLT3-mutated AML treated with venetoclax and azacitidine was 67% compared to 36% for patients receiving azacitidine monotherapy. The median OS was 12.5 months (95% CI: 7.3–19.2) compared to 8.6 months (95% CI: 5.9–14.7). Stratifying by FLT3-mutation type in patients treated with venetoclax and azacitidine, the CRc in patients with FLT3-ITD and FLT3-TKD mutations was 63% and 77%, respectively, and median OS was 9.9 months (95% CI: 5.3–17.6) and 19.2 months (95% CI: 1.8-NE), respectively. Venetoclax plus azacitidine remains the standard first-line therapy for patients with newly diagnosed FLT3-mutated AML who are deemed ineligible for intensive chemotherapy. However, the results of this pooled analysis showed that patients with FLT3-mutated AML treated with venetoclax + azacitidine had inferior survival outcomes, particularly those with FLT3-ITD mutations, in whom treatment success is often limited by the expansion of FLT3 dependent subclones. Therefore, more effective frontline treatment options are needed for patients with FLT3-mutated AML who are ineligible for intensive chemotherapy. Relapsed/refractory disease Gilteritinib and quizartinib are FLT3 inhibitors that provide the best evidence of efficacy in patients with relapsed/refractory (R/R) FLT3-mutated AML. In the phase III ADMIRAL trial, gilteritinib was shown to be associated with superior median OS compared to standard salvage chemotherapy (9.3 months versus 5.6 months; two-sided p < 0.001) for patients who had refractory disease after 1–2 cycles of anthracycline-containing induction therapy or who had hematologic relapse after achieving a prior remission. In this study, a higher percentage of patients in the gilteritinib arm underwent alloHSCT than in the chemotherapy arm. However, the survival benefit was maintained even when the survival data were censored at the time of transplantation (HR, 0.58; 95% CI: 0.43–0.76) [24]. Follow-up data were released 2 years after the primary analysis of the study, which confirmed the initial OS benefit and showed superior OS for gilteritinib at each time point analyzed (1, 2, and 3 years post-randomization) [25]. Based on these results, gilteritinib can be considered the standard of care for patients with R/R FLT3-mutated AML. Quizartinib has also been approved in certain countries as single-agent therapy for R/R disease (not currently FDA-approved in the USA). The QuANTUM-R trial analyzed the effects of quizartinib alone compared to those of investigator-selected chemotherapy in patients with R/R FLT3-ITD mutated AML. This study demonstrated that quizartinib was associated with a superior median OS compared to standard chemotherapy at 6.2 months versus 4.7 months (HR, 0.76; 95% CI: 0.58–0.98; p = 0.02). However, there were more treatment-related deaths in the quizartinib group (80 patients, 33% of the quizartinib arm population) than in the standard chemotherapy group (16 patients, 17% of the chemotherapy arm population), with a greater percentage attributed to adverse events (31% vs. 13%) [26]. Maintenance therapy after stem cell transplant FLT3 inhibitors have also been studied as maintenance therapies after alloHSCT. In the phase III MORPHO trial, gilteritinib was compared with a placebo as a post-transplant maintenance therapy for patients with FLT3-ITD-mutated AML who underwent alloHSCT in the first remission after receiving up to two cycles of intensive chemotherapy to attain remission. Patients enrolled in this trial began post-transplant gilteritinib or placebo after they had achieved engraftment, were free of grade II-IV graft-versus-host disease (GVHD) and, did not receive more than 0.5 mg/kg of prednisone daily. Patients initiated post-transplant maintenance therapy between days 30 and 90 following transplantation and continued maintenance therapy for up to 24 months. This study showed that patients who received gilteritinib after alloHSCT demonstrated superior relapse-free survival (RFS) (HR 0.679; 95% CI: 0.459–1.005; two-sided p = 0.0518). However, this difference was not statistically significant. In subgroup analysis, gilteritinib was associated with a statistically significant improvement in RFS in patients with detectable measurable residual disease (MRD) on immediate pre- or post-transplant assessments. MRD was assessed using PCR-NGS to detect the persistence of FLT3-ITD mutated transcripts [27]. Based on these results, gilteritinib is often used for post-transplant maintenance in this subset of patients with pre- or post-alloHSCT MRD. Sorafenib has also been shown to reduce the risk of relapse or death compared to placebo when used as post-alloHSCT maintenance therapy. The SORMAIN trial was a randomized, phase II, double-blind, placebo-controlled trial that included patients with FLT3-ITD mutated AML in complete hematologic remission following alloHSCT, both patients who underwent transplant following first-line induction therapy and those who underwent transplant for R/R disease. Patients were assigned to receive post-transplant sorafenib or placebo maintenance therapy, starting between days 60 and 100 after transplantation. Maintenance therapy was continued for up to 24 months. Treatment with maintenance sorafenib was associated with a decreased risk of relapse or death compared to placebo (HR 0.39; 95% CI: 0.18–0.85, p = 0.013), with a median follow-up of 41.8 months. The estimated RFS at 24 months post-transplant was 85.0% in the sorafenib arm versus 53.3% in the placebo arm (HR 0.256; 95% CI: 0.10–0.65, p = 0.002). There was no statistically significant difference in OS between the two treatment groups [28]. In another trial involving multiple hospitals in China, sorafenib was shown to significantly decrease the rate of relapse compared to placebo when administered as a post-transplant maintenance therapy. The one-year cumulative incidence of relapse was 24.5% in patients receiving placebo versus 7% in patients receiving sorafenib (HR 0.25; 95% CI: 0.11–0.57; p = 0.0010) [29]. Based on these results, sorafenib can be considered a post-transplant maintenance therapy in patients with FLT3-ITD mutated AML. However, toxicities associated with sorafenib often limit its use in clinical practice. For example, in the SORMAIN trial, 76.8% of patients treated with sorafenib maintenance developed grade 3 or higher acute GVHD, chronic GVHD, or both, and 22% of patients in the sorafenib arm discontinued treatment because of toxicity, compared to 5% in the placebo arm [28]. Safety considerations The use of FLT3 inhibitors in clinical practice has been associated with adverse effects. The most common adverse hematological effects are myelosuppression, pancytopenia, anemia, leukopenia, thrombocytopenia, and febrile neutropenia. The second most frequently reported class of side effects is gastrointestinal disorders, which include abdominal discomfort, constipation, diarrhea, nausea, vomiting, and elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels [30]. Quizartinib is associated with prolonged QTc. In the QuANTUM-First trial, 14% of the patients treated with quizartinib developed QTc prolongation, with 3% reported to have grade 3 or higher QTc prolongation, and 0.8% experienced ventricular fibrillation in the context of hypokalemia. Therefore, quizartinib carries a boxed warning for QT prolongation, and frequent EKGs with electrolyte monitoring are required while patients are receiving quizartinib [16, 31]. Gilteritinib was also associated with QTc prolongation with 4.9% of patients treated in the ADMIRAL trial experiencing QTc prolongation considered related to gilteritinib [24]. EKG monitoring is required for patients receiving gilteritinib. There are also case reports of differentiation syndrome in patients receiving gilteritinib, which is important for clinicians to consider when prescribing gilteritinib [32]. Ongoing investigation of FLT3 inhibitors Frontline therapy in patients eligible for intensive chemotherapy Gilteritinib A phase I trial combining gilteritinib with induction and consolidation chemotherapy demonstrated promising results with a 70.0% mutational clearance rate [33]. Subsequently, randomized trials combining gilteritinib with induction and consolidation chemotherapy were initiated. The initial results were reported from a randomized phase II trial in patients with newly diagnosed FLT3-ITD- or TKD-mutated AML conducted at academic medical centers in the United States. The patients enrolled in this trial received either gilteritinib or midostaurin in combination with 7 + 3 induction therapy and up to 4 cycles of cytarabine consolidation therapy. The patients underwent alloHSCT at any time after remission was achieved. Maintenance therapy was not included in the trial. The gilteritinib arm was associated with improved remission rates (85.6% CRc in the gilteritinib arm vs. 72.4% in the midostaurin arm; P = 0.042) and higher rates of MRD-negative remission after the first consolidation cycle. However, gilteritinib did not improve the rate of MRD-negative remission after induction, and the study did not meet the primary endpoint [34]. Long-term survival follow-up may help further elucidate the full impact of 7 + 3 + midostaurin compared to 7 + 3 + gilteritinib. A separate international trial (HOVON 156 AML) is currently underway. This randomized phase III trial enrolled patients newly diagnosed with AML or myelodysplastic syndrome with excess blasts-2 (MDS-EB2) harboring FLT3-ITD or FLT3-TKD mutations. The patients enrolled in this trial were randomized to receive gilteritinib or midostaurin combined with induction and consolidation chemotherapy (NCT04027309) [35]. The results of this trial will also help to elucidate the role of gilteritinib versus midostaurin in this setting. Crenolanib Results from an early phase trial of frontline chemotherapy combined with crenolanib have also been reported in patients with newly diagnosed FLT3-ITD or FLT3-TKD mutated AML. Patients received crenolanib in combination with 7 + 3 induction chemotherapy and cytarabine consolidation therapy. The patients underwent alloHSCT at the investigator’s discretion during the first remission. Crenolanib can be administered for up to 12 months as maintenance therapy following the completion of chemotherapy or stem cell transplantation. This treatment strategy was associated with a promising overall response rate (ORR) of 86% and a CR rate of 77%. The median OS was not reached, and the median EFS was 44.7 months at a median follow-up of 45 months [36]. Based on these promising results, an active randomized controlled trial is directly comparing 7 + 3 + crenolanib to 7 + 3 + midostaurin (NCT03258931) [37]. Frontline treatment in patients ineligible for intensive chemotherapy Research on new treatments for FLT3-mutated AML patients who are ineligible for intensive chemotherapy is an active area of ongoing investigation. The randomized phase III Lacewing trial compared treatment with gilteritinib + azacitidine to azacitidine monotherapy in patients with newly diagnosed FLT3-ITD or FLT3-TKD mutated AML who were deemed ineligible for intensive chemotherapy [38]. Median OS was not significantly different between the two arms at 9.82 months in patients treated with gilteritinib + azacitidine versus 8.87 months in patients treated with azacitidine monotherapy (HR, 0.916; 95% CI: 0.529–1.585; p = 0.753). Therefore, the study did not meet its primary endpoint and was closed early owing to futility according to the protocol-specified boundary. Treatment of FLT3-ITD mutated AML with FLT3-targeted tyrosine kinase inhibitors induces additional point mutations in the tyrosine kinase domain, most commonly within the D835 activation loop (FLT3-ITD/D835 mutated cells). One study found that these FLT3-ITD/D835 mutated cells had a higher activation of NF-κB signaling, leading to the upregulation of Bcl-2 gene expression. This suggests that upregulation of Bcl-2 gene expression and Bcl-2 protein production is an important mechanism leading to resistance to FLT3 inhibitors. Targeting the Bcl-2 protein may overcome the acquired resistance to FLT3 inhibition. Therefore, incorporation of the Bcl-2 inhibitor venetoclax may represent a viable therapeutic strategy to overcome this resistance mechanism [39]. There is promising early data from multiple studies on triplet therapies incorporating FLT3 inhibitors, venetoclax, and hypomethylating agents in the frontline setting. In a single-institution phase I/II study, Short et al. investigated the combination of gilteritinib + azacitidine + venetoclax in patients with newly diagnosed FLT3-ITD or TKD mutated AML deemed ineligible for intensive chemotherapy [40]. Early results indicated a CRc of 96%. At a median follow-up of 41.5 months, the median RFS was 23.4 months with a 3-year RFS rate of 43%. The median OS was 29.7 months with a 3-year OS rate of 46%. The results were also stratified according to FLT3 mutation subtype. For patients with FLT3-ITD mutations, the median OS was 21.8 months, and the 3-year OS was 36%. For patients with FLT3-TKD mutations, the median OS was not reached, and the 3-year OS rate was 75% [41]. A separate multicenter phase I/II trial is also investigating the triplet combination of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-ITD- or TKD-mutated AML who are ineligible for intensive chemotherapy (NCT05520567). This trial is ongoing and interim results have been reported. This study assessed two separate doses of venetoclax (200 mg and 400 mg) in the phase I portion, with 400 mg being the recommended phase II dose based on a preliminary safety analysis. Interim results were reported with a median follow-up of 14 months in the venetoclax 200 mg cohort and 12 months in the venetoclax 400 mg cohort. CR rates were 70% and 65% in each cohort, with 12-month OS rates of 64% and 77% [42]. Another phase I/II study in patients with FLT3-ITD mutated AML substituted decitabine for azacitidine and used quizartinib as the FLT3 inhibitor (venetoclax + decitabine + quizartinib) (NCT03661307). This study also found promising results, with a CRc rate of 95% and 1-year OS of 71% in this patient population [43]. Another phase I/II study assessed the regimen of venetoclax, decitabine, and FLT3 inhibitors (midostaurin, gilteritinib, or sorafenib) in patients with newly diagnosed FLT3-ITD or TKD-mutated AML aged greater than 60 years at the time of diagnosis (NCT03404193). This study found a CRc rate of 92% in this patient population, with a 2-year OS of 80% [44]. The Myelomatch (Myeloid Malignancies Molecular Analysis for Therapy Choice) initiative is a group of clinical trials for patients with newly diagnosed AML or MDS, sponsored by the National Cancer Institute (NCI) in the U.S. (NCT05564390). One current active treatment sub-study includes patients with newly diagnosed FLT3-ITD or FLT3-TKD-mutated AML who were deemed ineligible for intensive chemotherapy (NCT06317649). This is a randomized 3-arm study. The patients assigned to the control arm receive standard-of-care doublet therapy with venetoclax and azacitidine. The two experimental arms each involve triplet therapy with venetoclax + azacitidine + gilteritinib, with gilteritinib being administered in different schedules in each of these two arms. The results of this study will help answer the question of whether triplet therapy incorporating a FLT3 inhibitor yields superior efficacy compared with standard azacitidine + venetoclax. Relapsed/refractory disease A phase I/II dose-escalation, two-arm trial of crenolanib, paired with either intensive chemotherapy or azacitidine, demonstrated an ORR of 46% in patients with R/R FLT3-ITD- or TKD-mutated AML [45]. This provides opportunities for further exploration of crenolanib in this setting. There is currently an ongoing randomized clinical trial comparing crenolanib plus salvage chemotherapy with salvage chemotherapy alone (NCT03250338) [46]. Preliminary results demonstrated an improved ORR of 60% versus 39%, and a lower rate of refractory disease (placebo, 59% versus crenolanib, 34%). The addition of crenolanib also resulted in a longer median EFS (3.4 versus 0.0 months; HR 0.64; p = 0.0145) [47]. A trial from Japan assessed the efficacy of gilteritinib following salvage chemotherapy with mitoxantrone, etoposide, and cytarabine and reported preliminary results. The overall primary CR and CRc rate were 48.8%, and 87.8%, respectively. With a median follow-up time of 20.4 months, the median OS was 32.2 months, and median RFS was 29.3 months [48]. Triplet therapy regimens are also of interest for the treatment of R/R FLT3-mutated AML. The combination of venetoclax, azacitidine, and gilteritinib has been studied in patients with R/R AML, in addition to newly diagnosed AML. In a phase I/II single-center study, this combination resulted in complete remission (CR)/complete remission with incomplete count recovery (CRi) rate of 27% in the R/R population, and 41% of the R/R patients achieved a morphologic leukemia-free state (MLFS). The median OS of the R/R cohort was 5.8 months [40]. Another triplet combination that was studied was venetoclax, decitabine, and quizartinib. Initial results from a phase I/II trial of this combination were promising, with a CRc of 60%, CR/CRi of 28%, and a median OS of 6.3 months in patients with R/R disease [43]. Finally, a phase II trial analyzed the impact of venetoclax + azacitidine + the investigator’s choice of an FLT3 inhibitor. The CRc for patients with R/R FLT3-mutated AML was 62%, with an MRD negativity rate of 63% when analyzed by flow cytometry, and 100% when analyzed by PCR/NGS. In eight patients with prior FLT3 inhibitor exposure, CRc was 63% [44]. These results indicate the promising potential of triplet therapy combinations in R/R FLT3-mutated AML. Novel combinations and approaches FLT3 inhibitors in combination with menin inhibitors Menin, encoded by the MEN1 gene, is a nuclear scaffold protein that binds to the histone-lysine N-methyltransferase 2 A protein (also referred to as KMT2A), facilitating the transcription of genes encoding other transcription factors involved in hematopoiesis, including HOXA and MEIS1. Inhibition of the menin-KMT2A interaction by menin inhibitors has demonstrated efficacy in specific subtypes of AML, including AML harboring mutations in the NPM1 gene (NPM1m), rearrangements in the KMT2A gene (KMT2Ar), and rearrangements in the NUP98 gene (NUP98r) [49]. The menin inhibitor revumenib is currently FDA-approved as a monotherapy for the treatment of R/R KMT2Ar or NPM1m disease, based on the results of the Augment-101 study [50]. The menin inhibitor ziftomenib is now FDA-approved as a monotherapy for the treatment of R/R NPM1m AML, based on results from the KO-MEN-001 trial [51]. The Augment-101 trial found that treatment with revumenib led to downregulation of FLT3 transcription, likely because FLT3 is a transcriptional target of MEIS1. A pre-clinical 2020 study by Dzama et al. found that combining menin inhibition with FLT3 inhibition resulted in significantly reduced expression of FLT3, leading to the suppression of genes downstream of FLT3 signaling [52]. This study also found that the combination of menin and FLT3 inhibition led to synergistic inhibition of proliferation while augmenting apoptosis compared to single-agent menin or FLT3 inhibition in FLT3-mutated AML models. This preclinical evidence of synergy has led to interest in studying combination therapy with menin and FLT3 inhibition in clinical trials, several of which are ongoing. One early phase study assessed the effect of revumenib combined with gilteritinib in patients with R/R FLT3-mutated AML harboring a concurrent genetic alteration known to confer sensitivity to menin inhibition (NCT06222580). The results were reported for the first seven patients treated in this study and demonstrated promising preliminary safety and efficacy [53]. There is another ongoing early phase trial of ziftomenib in combination with quizartinib in patients with R/R disease (NCT06769490). The KO-MEN-007 trial is yet another ongoing multi-arm trial combining ziftomenib with additional agents in newly diagnosed and R/R settings (NCT05735184). One of the current open arms combines 7 + 3 induction chemotherapy with ziftomenib and quizartinib in patients newly diagnosed with FLT3-ITD and NPM1 co-mutated AML. Quizartinib for treatment of FLT3-wild type AML Another novel approach, recently studied in the Quiwi trial, incorporated FLT3 inhibition into the treatment of patients with FLT-3 wild type AML. This randomized phase II trial included patients newly diagnosed with FLT3-ITD wild-type AML who were deemed eligible for intensive chemotherapy. Patients were randomized to receive 7 + 3 + quizartinib or 7 + 3 + placebo. The quizartinib arm was associated with improved OS in this trial (not reached for quizartinib arm versus 29.3 months for placebo) (HR 0.625; 95% CI: 0.436–0.897; p = 0.009). This was likely due to off-target effects of quizartinib [54]. These positive findings led to the creation of a follow-up global phase III QUANTUM -WT study, which is an ongoing trial with the goal of further investigating this treatment strategy (NCT06578247). A summary of the key ongoing trials incorporating FLT3 inhibitors is presented in Table 1. Table 1Summary of key ongoing clinical trials incorporating FLT3 inhibitorsTrial NumberStatusDescriptionPreliminary ResultsNCT03836209Phase II7 + 3 + Gilteritinib versus 7 + 3 + midostaurin in ND FLT3-mutated AMLCRc: 85.6% for Gilteritinib versus 72.4% for Midostaurin (p = 0.042). MRD-negative CRc post induction was 64.4% for Gilteritinib and 59.8% for Midostaurin (p = 0.539)NCT04027309Phase III7 + 3 + Gilteritinib versus 7 + 3 + Midostaurin in ND FLT3-mutated AML and FLT3-mutated MDS-EB2NCT03258931Phase IIICrenolanib versus Midostaurin Following IC in ND FLT3-mutated AMLNCT03250338Phase IIIIC + Crenolanib versus IC + Placebo in R/R FLT3-mutated AMLCRc: 60% for Crenolanib versus 39% for Placebo. Median EFS 3.4 months for Crenolanib versus 0.0 months for Placebo (HR = 0.64; p = 0.0145)NCT04140487Phase I/IIAzacitidine + Venetoclax + Gilteritinib in ND FLT3-mutated AML ineligible for IC or R/R FLT3-mutated AMLND: CRc of 96% (CR of 90%). Median OS 29.7 monthsR/R: CR of 27%, MLFS of 41%. Median OS 5.8 monthsNCT05520567Phase I/IIAzacitidine + Venetoclax + Gilteritinib in ND FLT3-mutated AML ineligible for ICThe CR rate was 70% with ven 200 mg and 65% with ven 400 mg. 12-month OS rate of 64% with ven 200 mg and 77% with ven 400 mgNCT03661307Phase I/IIDecitabine + Venetoclax + Quizartinib in ND FLT3-ITD mutated AML ineligible for IC or R/R FLT3-mutated AMLND: CRc 95%. 1-year OS 71%R/R: CRc of 60%. Median OS 6.3 monthsNCT06317649Phase IIVenetoclax + Azacitidine versus Venetoclax, Azacitidine, and Gilteritinib in ND FLT3-mutated AML ineligible for ICNCT06222580Phase IGilteritinib + Revumenib in R/R FLT3-mutated AML harboring NPM1 mutation, KMT2A rearrangement, or other genetic alteration portending sensitivity to menin inhibitionFirst 6 efficacy evaluable patients: 2 with MLFS and 1 with MRD-negative CRNCT06769490Phase IQuizartinib + Ziftomenib in R/R FLT3-ITD mutated AMLNCT05735184Phase IMulti-arm study including 7 + 3 + Ziftomenib + Quizartinib in ND FLT3-ITD mutated AML with NPM1 co-mutationNCT04107727Phase II (Completed)7 + 3 + Quizartinib versus 7 + 3 + placebo regimens in FLT3-ITD wild type AMLMedian OS NR in Quizartinib arm and 29.3 months in placebo arm with median follow-up of 39.4 months (HR 0.625; 95% CI: 0.436–0.897; p = 0.009)NCT06578247Phase III7 + 3 + Quizartinib versus 7 + 3 + placebo in FLT3-ITD wild type AML eligible to receive intensive chemotherapyAbbreviations: 7 + 3 cytarabine + anthracycline chemotherapy, ND Newly diagnosed, FLT3 FMS-Like Tyrosine kinase 3, AML Acute myeloid leukemia, CR Complete remission, CRc Composite complete remission, IC Intensive chemotherapy, R/R Relapsed/refractory, EFS Event-free survival, HR Hazard ratio, OS Overall survival, MDS-EB2 Myelodysplastic syndrome with excess blasts 2, ITD Internal Tandem Duplication Table 1Summary of key ongoing clinical trials incorporating FLT3 inhibitorsTrial NumberStatusDescriptionPreliminary ResultsNCT03836209Phase II7 + 3 + Gilteritinib versus 7 + 3 + midostaurin in ND FLT3-mutated AMLCRc: 85.6% for Gilteritinib versus 72.4% for Midostaurin (p = 0.042). MRD-negative CRc post induction was 64.4% for Gilteritinib and 59.8% for Midostaurin (p = 0.539)NCT04027309Phase III7 + 3 + Gilteritinib versus 7 + 3 + Midostaurin in ND FLT3-mutated AML and FLT3-mutated MDS-EB2NCT03258931Phase IIICrenolanib versus Midostaurin Following IC in ND FLT3-mutated AMLNCT03250338Phase IIIIC + Crenolanib versus IC + Placebo in R/R FLT3-mutated AMLCRc: 60% for Crenolanib versus 39% for Placebo. Median EFS 3.4 months for Crenolanib versus 0.0 months for Placebo (HR = 0.64; p = 0.0145)NCT04140487Phase I/IIAzacitidine + Venetoclax + Gilteritinib in ND FLT3-mutated AML ineligible for IC or R/R FLT3-mutated AMLND: CRc of 96% (CR of 90%). Median OS 29.7 monthsR/R: CR of 27%, MLFS of 41%. Median OS 5.8 monthsNCT05520567Phase I/IIAzacitidine + Venetoclax + Gilteritinib in ND FLT3-mutated AML ineligible for ICThe CR rate was 70% with ven 200 mg and 65% with ven 400 mg. 12-month OS rate of 64% with ven 200 mg and 77% with ven 400 mgNCT03661307Phase I/IIDecitabine + Venetoclax + Quizartinib in ND FLT3-ITD mutated AML ineligible for IC or R/R FLT3-mutated AMLND: CRc 95%. 1-year OS 71%R/R: CRc of 60%. Median OS 6.3 monthsNCT06317649Phase IIVenetoclax + Azacitidine versus Venetoclax, Azacitidine, and Gilteritinib in ND FLT3-mutated AML ineligible for ICNCT06222580Phase IGilteritinib + Revumenib in R/R FLT3-mutated AML harboring NPM1 mutation, KMT2A rearrangement, or other genetic alteration portending sensitivity to menin inhibitionFirst 6 efficacy evaluable patients: 2 with MLFS and 1 with MRD-negative CRNCT06769490Phase IQuizartinib + Ziftomenib in R/R FLT3-ITD mutated AMLNCT05735184Phase IMulti-arm study including 7 + 3 + Ziftomenib + Quizartinib in ND FLT3-ITD mutated AML with NPM1 co-mutationNCT04107727Phase II (Completed)7 + 3 + Quizartinib versus 7 + 3 + placebo regimens in FLT3-ITD wild type AMLMedian OS NR in Quizartinib arm and 29.3 months in placebo arm with median follow-up of 39.4 months (HR 0.625; 95% CI: 0.436–0.897; p = 0.009)NCT06578247Phase III7 + 3 + Quizartinib versus 7 + 3 + placebo in FLT3-ITD wild type AML eligible to receive intensive chemotherapyAbbreviations: 7 + 3 cytarabine + anthracycline chemotherapy, ND Newly diagnosed, FLT3 FMS-Like Tyrosine kinase 3, AML Acute myeloid leukemia, CR Complete remission, CRc Composite complete remission, IC Intensive chemotherapy, R/R Relapsed/refractory, EFS Event-free survival, HR Hazard ratio, OS Overall survival, MDS-EB2 Myelodysplastic syndrome with excess blasts 2, ITD Internal Tandem Duplication Summary of key ongoing clinical trials incorporating FLT3 inhibitors ND: CRc of 96% (CR of 90%). Median OS 29.7 months R/R: CR of 27%, MLFS of 41%. Median OS 5.8 months ND: CRc 95%. 1-year OS 71% R/R: CRc of 60%. Median OS 6.3 months Abbreviations: 7 + 3 cytarabine + anthracycline chemotherapy, ND Newly diagnosed, FLT3 FMS-Like Tyrosine kinase 3, AML Acute myeloid leukemia, CR Complete remission, CRc Composite complete remission, IC Intensive chemotherapy, R/R Relapsed/refractory, EFS Event-free survival, HR Hazard ratio, OS Overall survival, MDS-EB2 Myelodysplastic syndrome with excess blasts 2, ITD Internal Tandem Duplication Conclusion The expansion of targeted therapies has significantly improved the treatment of patients with various subsets of AML, including FLT3-mutated AML, which accounts for approximately 30% of newly diagnosed AML cases. The addition of the FLT3 inhibitors midostaurin and quizartinib to intensive chemotherapy has improved the outcomes of patients who are candidates for intensive chemotherapy. Gilteritinib monotherapy has become the standard of care for patients with R/R FLT3-mutated AML. Despite these advances, unmet needs remain for FLT3-mutated AML, including improved frontline treatment options for patients who are not eligible for intensive chemotherapy, improved outcomes in patients with R/R disease, and overcoming the resistance to FLT3 inhibitors. These are areas of active investigation with promising ongoing research, as highlighted in this review. The future of AML treatment remains promising, with the hope of continued improvement in outcomes for patients with FLT3-mutated AML and other AML subsets in the years ahead.